🟢 NanoViricides is trading 6.33% up today on investor interest in Phase II Ebola trial

NanoViricides is trading 6.33% up at $1.56 as investor interest continues around its Phase II NV-387 oral-gummy Ebola trial.

• The trial is scheduled to begin during the week of September 21, 2026, in the Democratic Republic of Congo.
• The adaptive study will evaluate safety, dosing, and efficacy against Bundibugyo and other Ebola viruses.
• Gains extend September 16-17; the catalyst is company-specific, though broader risk-on conditions may add support. Registration and regulatory approval were announced before September 21.